skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

The Respiratory Effectiveness Group (REG) Summit, which took place on 28–29 June 2014, provided clinicians, general practitioners, pulmonologists, and representatives from the industry with the opportunity to discuss real-life effectiveness research in respiratory disease. This white paper presents research from studies identified of particular relevant to the asthma and COPD markets which revealed:


  • The potential benefits that Symbicort (budesonide/formoterol; AstraZeneca) may have over Spiriva (tiotropium; Boehringer Ingelheim) in the treatment of COPD in terms of both patient outcomes, as assessed by measuring COPD exacerbations, and healthcare utilization costs.
  • The value of add-on Spiriva therapy in asthma as Boehringer Ingelheim prepares to expand Spiriva’s indications in the EU.
  • That inhaled corticosteroid (ICS)/long-acting beta 2 agonist (LABA) therapy can improve long-term outcomes among patients that have experienced a severe asthma exacerbation.
  • That the prescribing behavior of physicians does not necessarily fall in line with step-up therapy guidelines.





電話:+81 (0)3 6273 4260